Beijing Shenogen Biomedical Co., Ltd
Quick facts
Phase 3 pipeline
- HUACHANSU PIAN · Oncology
Huachansu is a traditional Chinese medicine extract derived from toad secretions that contains bufadienolides and other bioactive compounds with potential anti-tumor and immunomodulatory properties. - Sorafenib Tosylate Tablets · Oncology
Sorafenib Tosylate Tablets inhibit multiple intracellular and cell surface kinases, which are involved in tumor growth and angiogenesis.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Beijing Shenogen Biomedical Co., Ltd portfolio CI brief
- Beijing Shenogen Biomedical Co., Ltd pipeline updates RSS
Frequently asked questions about Beijing Shenogen Biomedical Co., Ltd
What is Beijing Shenogen Biomedical Co., Ltd's pipeline?
Beijing Shenogen Biomedical Co., Ltd has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include HUACHANSU PIAN, Sorafenib Tosylate Tablets.
Related
- Sector hub: All tracked pharma companies